Despite accruing evidence suggesting that GLP-1R agonists may benefit cognitive and motor functions in AD and PD (Holscher, 2022), it remains unclear which mitochondrial markers (Tomas et al., 2011; Morales et al., 2014; Holscher, 2024) can explain their efficacy in both conditions. The gene discussed is GLP1R; the disease is Parkinson disease.